Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vladimir Coric

Showing results (71-80 of 84) with videos related to

Pageof 9
Sort By:
Journal of Affective Disorders|July 7, 2009
Dimensional predictors of response to SRI pharmacotherapy in obsessive-compulsive disorderAngeli Landeros-Weisenberger, Michael H Bloch, Ben Kelmendi, et al.
Biological Psychiatry|July 5, 2005
Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trialVladimir Coric, Sarper Taskiran, Christopher Pittenger, et al.
Breastfeeding Medicine : the Official Journal of the Academy of Breastfeeding Medicine|January 20, 2022
Human Milk and Plasma Pharmacokinetics of Single-Dose Rimegepant 75 mg in Healthy Lactating WomenTeresa E Baker, Robert Croop, Lisa Kamen, et al.
Depression and Anxiety|March 28, 2013
Long-term outcome in adults with obsessive-compulsive disorderMichael H Bloch, Christy Green, Stephen A Kichuk, et al.
Neuroscience Letters|May 3, 2011
Association of polymorphisms in HCN4 with mood disorders and obsessive compulsive disorderBenjamin Kelmendi, Márcia Holsbach-Beltrame, Andrew M McIntosh, et al.
Alzheimer'S Research & Therapy|May 2, 2025
Prognostic value of plasma biomarkers for informing clinical trial design in mild-to-moderate Alzheimer's diseaseYuqi Qiu, Diane M Jacobs, Karen Messer, et al.
Depression and Anxiety|May 11, 2010
Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorderVladimir Coric, Howard H Feldman, Dan A Oren, et al.
Archives of Neurology|August 16, 2012
Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer diseaseVladimir Coric, Christopher H van Dyck, Stephen Salloway, et al.
Journal for Immunotherapy of Cancer|May 19, 2016
Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial gliomaMira A Patel, Jennifer E Kim, Debebe Theodros, et al.
Journal for Immunotherapy of Cancer|November 9, 2016
Erratum to: Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial gliomaMira A Patel, Jennifer E Kim, Debebe Theodros, et al.
Pageof 9

Showing results (71-80 of 84) with videos related to

Sort By:
Pageof 9
Journal of Affective Disorders|July 7, 2009
Dimensional predictors of response to SRI pharmacotherapy in obsessive-compulsive disorderAngeli Landeros-Weisenberger, Michael H Bloch, Ben Kelmendi, et al.
Biological Psychiatry|July 5, 2005
Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trialVladimir Coric, Sarper Taskiran, Christopher Pittenger, et al.
Breastfeeding Medicine : the Official Journal of the Academy of Breastfeeding Medicine|January 20, 2022
Human Milk and Plasma Pharmacokinetics of Single-Dose Rimegepant 75 mg in Healthy Lactating WomenTeresa E Baker, Robert Croop, Lisa Kamen, et al.
Depression and Anxiety|March 28, 2013
Long-term outcome in adults with obsessive-compulsive disorderMichael H Bloch, Christy Green, Stephen A Kichuk, et al.
Neuroscience Letters|May 3, 2011
Association of polymorphisms in HCN4 with mood disorders and obsessive compulsive disorderBenjamin Kelmendi, Márcia Holsbach-Beltrame, Andrew M McIntosh, et al.
Alzheimer'S Research & Therapy|May 2, 2025
Prognostic value of plasma biomarkers for informing clinical trial design in mild-to-moderate Alzheimer's diseaseYuqi Qiu, Diane M Jacobs, Karen Messer, et al.
Depression and Anxiety|May 11, 2010
Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorderVladimir Coric, Howard H Feldman, Dan A Oren, et al.
Archives of Neurology|August 16, 2012
Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer diseaseVladimir Coric, Christopher H van Dyck, Stephen Salloway, et al.
Journal for Immunotherapy of Cancer|May 19, 2016
Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial gliomaMira A Patel, Jennifer E Kim, Debebe Theodros, et al.
Journal for Immunotherapy of Cancer|November 9, 2016
Erratum to: Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial gliomaMira A Patel, Jennifer E Kim, Debebe Theodros, et al.
Pageof 9